Oppenheimer Lowers Emerson Rating to Perform Citing Limited Upside at Current Valuation
Oppenheimer has moved Emerson (NYSE: EMR) from Outperform to Perform, noting the share price is trading very close to its previous $152 price target and that current valuation metrics leave little room for near-term upside. The firm recognized Emerson's operational strengths but flagged a subdued organic growth profile concentrated in the second ha…